SAN DIEGO—Ma Songjiang, President of Gyre Therapeutics, Inc. (NASDAQ:GYRE), recently disclosed the sale of company shares valued at $49,600. The transactions, executed under a pre-established Rule 10b5-1 trading plan, occurred on December 30 and 31, 2024. The sale comes as GYRE shares have declined nearly 8% over the past week, with the stock currently trading at $12, significantly below its 52-week high of $27.45.
Songjiang sold a total of 4,000 shares of common stock, with the sale prices ranging from $12.3 to $12.5 per share. Following these transactions, Songjiang retains indirect ownership of 2,922,467 shares, held by a spouse. According to InvestingPro, GYRE maintains strong liquidity with a current ratio of 3.72 and operates with minimal debt, though the company is currently trading above its Fair Value estimate.
These transactions were carried out as part of a structured trading plan designed to provide a systematic approach to stock sales, ensuring compliance with insider trading regulations. Want deeper insights? InvestingPro subscribers have access to 7 additional ProTips and comprehensive financial metrics for GYRE.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.